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Abstract
Background: Lack of time and competing demands limit the ability of patients and providers to
engage in informed decision-making discussions about prostate cancer screening during primary
care visits. We evaluated a patient recall invervention to mitigate these challenges.
Methods: Using mail and telephone outreach we invited men age 50-74 years without a PSA test
in the prior 12 months to make appointments with their primary care providers in order to discuss
the pros and cons of PSA-based prostate cancer screening. We assessed patient responsiveness to
the program, provider documentation of screening discussions, orders for PSA laboratories, and
provider attitudes.
Results:  Out of 80 eligible patients, 37 (46%) scheduled and 28 (35%) completed a recall
appointment. A large majority (91%) of patients eligible for PSA screening received an order for
this test. Providers documented PSA discussions more often for these patients than for a recent
sample of their other patients who received traditional care (47.8% vs. 12.5%, p = 0.009). Twelve
of 14 participating providers felt the program improved their ability to impart information about
the risks and benefits of screening, but were uncertain whether it influenced their patients'
preexisting preferences for screening. Some expressed doubts about the advisability of PSA-specific
appointments.
Conclusion:  To a limited extent, this pilot recall intervention enhanced opportunities for
discussions of prostate cancer screening between patients and their primary care providers. As
currently configured, however, this program was not found to be feasible for this purpose. A future
version should promote screening discussions in the context of a broader range of health
maintenance concerns and include more detailed, low-literacy information to educate patients in
advance of clinic visits.
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Background
Prostate cancer is the second-leading cause of cancer death
in men over the age of 50. The prostate specific antigen
(PSA) test combined with a digital rectal exam (DRE) can
detect prostate cancer early; however, there is little high-
quality evidence that screening and current treatments,
many of which have disabling side effects, reduce mortal-
ity [1]. For this reason, professional organizations includ-
ing the American Cancer Society and the United States
Preventive Services Task Force (USPSTF) recommend that
before proceeding with screening, men have an informed
discussion with their health care providers regarding the
risks and benefits of the PSA test [2]. Unfortunately, this
recommendation is extremely challenging to implement
[3]. The issues and terminology are complex and fre-
quently difficult for patients to understand [4]. Often,
providers have time to focus only on acute concerns dur-
ing clinic visits, referring patients for a PSA test without a
discussion of its pros and cons [5]. In addition, providers
who are unaware of screening guidelines may assign lim-
ited importance to informed decision-making or may be
inexperienced with such discussions [6].
In response to these challenges, efforts have focused on
educating and activating patients for discussions through
the use of decision aids and other educational materials.
A few studies have demonstrated that decision aids are
associated with increased knowledge and reduced screen-
ing rates [7,8]. Personnel and space constraints, however,
limit the ability of many medical practices to deliver these
materials to patients immediately prior to office visits. In
addition, because of time pressures and uncomfortable
accommodations, the clinic setting may not be an optimal
environment for learning.
Here, we evaluate a modified approach to informed deci-
sion-making for prostate cancer screening. The approach
involves using a registry to identify patients eligible for
PSA screening and proactively outreaching to these
patients by mail and telephone in order to schedule
appointments specifically intended to facilitate meaning-
ful discussions with medical providers about the risks and
benefits of screening. The goal is to give patients the
opportunity to consider a brief educational message at lei-
sure in their home environment while providing ample
time in clinic to discuss PSA screening with medical pro-
viders. We assessed the operational feasibility of the pro-
gram; level of patient willingness to schedule and
complete decision-making appointments; documentation
of PSA screening discussions during clinic visits; rates of
PSA ordering; and provider feedback about the program.
Methods
Study Setting
This study was conducted in a large ambulatory primary
care practice affiliated with the University of Colorado
Hospital (UCH). The practice provides primary care to a
diverse patient population (approximately 50,000 visits
per year) and is staffed by 40 attending physicians, four
nurse practitioners, and 20 primary care residents. Attend-
ing providers were consulted and agreed ahead of time to
participate in the pilot program described below.
Patient Population
Based on automated electronic health record (EHR, Alls-
cripts Touchworks, version 10, Chicago, IL) abstraction,
men were deemed to meet initial inclusion criteria if they
were age 50 to 74 years, had an attending (rather than res-
ident) primary care provider (PCP), had seen a PCP in the
practice at least once in the preceding 18 months (to min-
imize the inclusion of patients no longer receiving care in
the system), and did not have an administrative claim for
a PSA test within the past 12 months (to coincide with
standard recommendations for screening on a yearly basis
if screening is to be carried out). Through a subsequent
manual review process, men from this initial sample were
excluded from outreach if they had clinic notes indicating
an active cancer or a terminal diagnosis; were deceased; or
no longer appeared to be receiving care within the system.
In addition, men were excluded if PSA testing would not
be warranted for screening purposes because of a history of
prostate cancer or a previously elevated PSA result or pros-
tate nodule. In other words, it is often not possible to
determine eligibility based on automated (computer-
based) EHR-review alone; a manual review of the EHR as
well as patient return postcards and telephone contact are
often necessary to identify patients who have received PSA
screening outside the system in the specified time frame
(12 months), who are no longer receiving care in the sys-
tem (more likely if they inform us of same or have not
received care in the system in >18 months), and who are
ineligible for PSA screening. Such patients, once identified,
are deemed ineligible and not offered phone-based
appointment scheduling.
Intervention Description and Implementation
Registry records of men meeting initial inclusion criteria
were imported into an information management utility
developed for this and other preventive and chronic dis-
ease outreach interventions [9-12]. The presence of exclu-
sionary criteria was determined for a randomly-selected
sample of these men by means of manual review of the
electronic health record. This process proceeded until a
final sample of between 100 and 120 men was identified
as eligible for outreach. Based on prior experience, we esti-
mated that 25-30% of these men would subsequently be
deemed ineligible for participation in the program basedBMC Family Practice 2009, 10:75 http://www.biomedcentral.com/1471-2296/10/75
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on information obtained through the outreach process
and, accordingly, would not be offered appointment
scheduling over the phone (e.g. no longer receiving care in
the system, received PSA screening outside the system,
deceased). The final eligible sample, estimated to include
75-100 men, would be sufficient for assessing the opera-
tional feasibility of the program.
The information management utility generated invitation
letters to be mailed to each patient's home. Each letter,
bearing the name of the patient's PCP on the signature
line, included the following message: "The PSA test can
help doctors find and treat prostate cancer at an early
stage, but the test is not perfect and does have potential
downsides. Believe it or not, for example, there is still a
lack of evidence that prostate cancer screening saves lives.
Also, this type of screening can sometimes lead to unnec-
essary treatments that cause permanent side effects. Can-
cer prevention experts recommend that men speak with
their doctors about the PSA test before going ahead with
screening. The goal of a visit with your primary care pro-
vider is not to get prostate cancer screening but to help
you make an informed decision about whether to get pros-
tate cancer screening." The letter encouraged the patient to
contact our call center to schedule a PCP appointment to
discuss PSA screening. A postage-paid return postcard
accompanied each letter on which the patient could indi-
cate whether he had recently had a PSA test outside of the
health system, no longer received primary care within the
system, was uninterested in discussing PSA screening, or
preferred to be contacted at a specified time and tele-
phone number. If the patient did not respond to the letter
within two weeks by postcard or phone, an outreach coor-
dinator (OC) made up to three calls to his home at vari-
ous times of day, leaving a voice message on the first and
last attempts. If a patient could not be reached after three
calls had been made, he was considered a passive decliner
of a PSA screening discussion.
If telephone contact was established, the OC reviewed the
rationale for having a discussion about PSA screening (i.e.
men should know the pros and cons of prostate cancer
screening before making a decision and the PCP will be
able explain these). If the patient accepted, the OC sched-
uled a 20-minute appointment over the telephone. The
OC then sent a brief note to the PCP via the EHR summa-
rizing the purpose of the upcoming visit: "Patient X has
scheduled an appointment with you at date/time to dis-
cuss prostate cancer screening. As you know, there are
benefits and risks to such screening and it is important for
men to be informed before making this decision. An
informed decision-making reference is available at the fol-
lowing website: <url>" [13]. Finally, the OC mailed a
reminder postcard to the patient noting the date, time,
and location of the appointment. The call center was
staffed between the hours of 8:00 am and 6:00 pm, Mon-
day through Friday; at other times patients could leave
messages requesting a callback. The outreach intervention
was conducted between August 1 and September 9, 2008.
Primary Outcomes
We assessed the following outcomes:
Appointment scheduling and completion
These were characterized as the proportions of eligible
participants who, during and after mail and telephone
outreach, scheduled and completed an appointment with
a PCP to discuss prostate cancer screening. Only those
patients who scheduled an appointment with an OC
through the call center (as opposed to the usual clinic
scheduling line), and who received verbal information
from an OC about the informed decision-making purpose
of the clinic visit, were considered to be responsive to the
program.
Provider documentation of prostate cancer screening discussions and 
comparisons with traditional care
We determined the proportion of patients whose provid-
ers documented PSA screening discussions in the EHR
during appointments scheduled for this purpose. Two
research assistants also independently characterized the
content of the clinic notes according to the presence or
absence of three types of elements: (1) PSA discussion -
generic reference to or specific details evidencing at least
some screening "discussion" or "conversation"; (2) At
least one downside - generic reference to having discussed,
or specific documentation of, at least one downside of
PSA screening; and (3) Patient preference - documentation
that the patient did or did not wish to proceed with
screening. For each provider who had at least one patient
that completed a recall visit for the purpose of a screening
discussion, we carried out a similar review of EHR docu-
mentation for the three most recent patients for whom the
same provider completed PSA screening during a period
immediately preceding implementation of the interven-
tion. Based on USPSTF guidelines, these patients should
(ideally) have engaged in a decision-making discussion
before completing screening, which should have been
documented in the EHR. We regarded these patients as
having received traditional care. In other words, theoreti-
cally for this group, decision-making discussions could
have taken place opportunistically during traditionally-
arranged, episodic clinic visits (as opposed to clinic visits
scheduled specifically for the purpose of carrying out such
discussions). We then compared traditional and interven-
tion care in terms of the presence of each type of docu-
mentation element.BMC Family Practice 2009, 10:75 http://www.biomedcentral.com/1471-2296/10/75
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PSA ordering
The rate of PSA ordering was characterized as the propor-
tion of screen-eligible patients whose providers ordered or
indicated an intention to order a PSA screening test during
the clinic visit.
Provider Feedback
We devised a brief online survey which we administered
after the intervention to participating providers in order to
assess their open-ended opinions about their willingness
to discuss PSA screening with patients; the value they
place on such discussions; the mechanics of the interven-
tion; and perceived effects on quality of care.
Statistical Methods
Statistical procedures were performed using STATA (ver-
sion 8.0, College Station, TX). Chi-square tests were used
to determine the strength of association between patient
characteristics (age, race/ethnicity, marital status, and his-
tory of prior PSA screening in the health system) and will-
ingness to schedule an appointment. Non-parametric
Mann-Whitney tests were used to derive aggregate com-
parison measures of participating providers in terms of
their average rates of including EHR documentation of
screening discussion elements during traditional care and
intervention-related visits. Descriptive statistics and
quotes illustrative of recurrent themes were used to char-
acterize the results of the provider survey.
Institutional Review Board
This intervention was designed and carried out as a qual-
ity improvement research program that relied on standard
methods for creating patient registries and providing
patient outreach. The Colorado Multiple Institution
Review Board approved publication of results following
the removal of personal health information.
Results
Of the 154 patients who met initial, automated inclusion
criteria, 40 (26%) were identified as meeting one or more
exclusion criteria after brief manual review, leaving 114 in
outreach sample. Characteristics of 80 patients deemed
eligible for program participation after outreach was com-
pleted are summarized in Table 1. Of these, 37 patients
(46%) scheduled an appointment through the call center.
In this relatively small sample, patient characteristics were
not associated with a willingness to schedule an appoint-
ment. Of 15 patients who, in responding to outreach, said
they were not interested in making an appointment, 8
reported that they had previously had a decision-making
discussion with their PCP and did not want to complete
screening. However, no patient said he declined to sched-
ule an appointment because of information contained in
the outreach materials.
Patient and provider responsiveness at various points dur-
ing the intervention process are summarized in Figure 1.
Ultimately, 23 patients truly eligible for prostate cancer
screening completed an appointment with one of 14
PCPs. Twenty-one (91%) of these patients received an
order for a PSA test. Only one patient declined PSA screen-
ing as a result of a discussion with his provider. In another
instance, the patient and provider appear to have focused
on issues other than prostate cancer screening. In compar-
ison with traditional care provided by the same PCPs,
patients with intervention-related visits were several times
more likely to have clinic notes that explicitly docu-
mented a discussion about screening and that made refer-
ence to at least one downside of screening. Meanwhile,
there was no significant difference in the presence of doc-
umentation regarding the patient's final screening prefer-
ence (Table 2).
Thirty-seven attending PCPs (93% of the total sample)
who responded to the survey, including 14 that partici-
pated in intervention-related visits, agreed that discus-
sions of the risks and benefits of screening are somewhat
to very important. At the same time, however, two-thirds
of respondents reported that such discussions are very
challenging and rarely take place, even when extra time is
made available. Said one provider, "Competing demands,
time, and complexity of working through the hypotheti-
cals are probably the biggest challenges. The near univer-
sal message in the media that men should have prostate
screening also presents a challenge." Twelve of 14 PCPs
who participated in intervention-related visits felt that
their ability to share information about screening was
enhanced, but most remained uncertain whether the extra
time and information did much to sway their patients' a
priori  preferences. Primarily because of problems with
patient access, a third of all respondents felt that prostate
cancer screening and associated discussions should not be
separated out from a longer annual exam in which other
preventive health concerns are addressed. Finally, three-
fourths of respondents were willing to let a mid-level pro-
vider (physician's assistant or nurse practitioner) carry out
prostate cancer screening discussions on their behalf, but
one detractor suggested that this would only "increase the
level of fragmentation" in patient care.
Discussion
Given the uncertain benefits and risks of harm associated
with PSA-based screening, patients should participate in
an informed decision-making process about this test [14].
However, lack of comprehension of common prostate
cancer terms, especially among low-literacy populations,
as well as a lack of time during clinic visits, are key barriers
to high-quality discussions [4,5]. Accordingly, we evalu-
ated a patient recall intervention designed to activate
patients and PCPs for discussions about the pros and consBMC Family Practice 2009, 10:75 http://www.biomedcentral.com/1471-2296/10/75
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of prostate cancer screening and to provide sufficient time
for carrying out such discussions. Approximately 30% of
eligible patients completed clinic visits for this purpose, a
respectable rate that is commensurate with what we have
obtained using a very similar intervention for other pre-
ventive services [11,12]. Second, providers believed that,
despite having an uncertain influence on patient prefer-
ences, the program helped to improve the process of edu-
cating patients. Finally, for these patients, screening
discussions were documented much more frequently than
for patients who completed screening through traditional
care. In these ways, the program was found to be opera-
tionally feasible.
In a larger sense, however, it remains unclear whether the
pilot program achieved its key objective, which is to help
patients make genuinely informed decisions about
screening. First, whereas we would have hoped that docu-
mentation of a discussion would have been evident in all
of the intervention clinic visit notes, such documentation
was present in less than half of these. Second, it is doubt-
ful that all patients responded with equal enthusiasm to
the offer of a conversation about screening. For example,
patients whose primary motivation was to complete
screening might have been more likely to schedule
appointments in order to complete screening. For these
patients, discussions may have done little to change their
Table 1: Patients eligible for PSA screening discussion and proportion scheduling a provider visit for this purpose (n = 80)
Characteristic N (%) N (%) that scheduled appointment*
Age
50-64 60 (75%) 32/60 (53%)
65+ 20 (25%) 5/20 (25%)
Marital Status
Married 58 (73%) 28/58 (48%)
Not Married 19 (24%) 8/19 (42%)
Unknown 3 (4%) 1/3 (33%)
Race/ethnicity
White 42 (53%) 20/42 (48%)
Black 12 (15%) 7/12 (58%)
Other/Unknown 26 (32%) 10/26 (38%)
History of PSA test at UCH†
Yes 41 (51%) 22/41 (55%)
No 39 (49%) 15/39 (39%)
TOTAL 80 37/80 (46%)
* Chi-square p was non-significant across all measured characteristics.
† UCH = University of Colorado Hospital and Clinics.BMC Family Practice 2009, 10:75 http://www.biomedcentral.com/1471-2296/10/75
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Patient and provider responsiveness to recall intervention Figure 1
Patient and provider responsiveness to recall intervention. †UCH = University of Colorado Hospital and Clinics.
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minds (we observed, for example, that PCPs ordered a
PSA test for almost all patients who completed visits).
Meanwhile, patients with little interest in screening at the
time of outreach, or after receiving a letter, might not have
found the offer of a discussion particularly compelling
and therefore may have declined to schedule one. On the
other hand, we noted that half of these patients declined
to schedule a visit because they had already made a deci-
sion to forego screening based on a prior conversation
with their PCP about the topic. This supports the idea that
such discussions can have an important influence on
patient attitudes and behavior. A key question, then, is
whether a patient recall program can motivate appoint-
ment scheduling among patients with ill-defined prefer-
ences for PSA screening.
These considerations, in addition to provider feedback
about access problems in the clinic, suggest that a future
recall program would be more effective if it facilitated PSA
discussions within the context of addressing a larger set of
health maintenance concerns. We did not wish to over-
whelm patients with written information about prostate
cancer screening, but earlier work suggests it may none-
theless be beneficial to include with the outreach materi-
als more robust, low-health literacy educational materials
or a PSA decision aid as these could help patients focus
and be more prepared for discussions when they finally
take place [15].
We remain intrigued by a patient-centered medical home
model of team-based care in which - instead of physicians
- mid-level providers, including nurse practitioners and
physician's assistants, assume greater responsibility for
the provision of primary prevention services [16]. With
proper training and experience, these providers could
become adept at leading patients through the challenges
of an informed decision-making process. Educating
patients about this arrangement and ensuring effective
care coordination, however, would be necessary in order
to overcome legitimate concerns about fragmented care.
While this study offers lessons for future work in prostate
cancer screening informed-decision-making, it does have
important limitations. The intervention included a rela-
tively small number of patients, precluding meaningful
subgroup analysis, and was performed in a single aca-
demic healthcare setting that is not representative of other
types of practice environments. We did not assess patient
knowledge, screening preferences, decision-making locus,
and satisfaction before or after clinic visits. The lack of
documentation of PSA discussions among some patients
in the intervention group does not mean that such discus-
sions did not take place. Similarly, it was not practically
feasible to identify patients receiving traditional care who
discussed PSA screening and whose providers, as a conse-
quence, did not order a PSA test. Nonetheless, we believe
that where PSA tests were ordered, the intervention and
traditional care differences in documentation are signifi-
cant and likely to reflect meaningful differences in the fre-
quency and quality of the decision-making process.
Future versions of this intervention should improve accu-
racy in the eligibility review process (e.g. better identifica-
tion and exclusion of patients with previously-elevated
PSA results) as well as accord greater attention to variables
that are likely to influence cost-effectiveness and long-
term sustainability (e.g. costs of staffing, increases in clinic
visit volume).
Despite these limitations, this work had some strengths.
First, under a low-risk clinical quality improvement
umbrella, we were able to avoid selection bias by extend-
ing outreach to all men who were eligible for PSA screen-
ing rather than limiting participation to patients who
formally consented to participation in a study. In contrast,
prior studies of interventions to improve informed deci-
sion-making have limited participation to patients who
provide written informed consent ahead of time [17,18],
who have internet access [17], who are already scheduled
for a PCP visit [8,15,17,18], or who are seeking a free PSA
test [19]. Second, with rare exceptions [15,20], few prior
studies have determined whether provider-patient discus-
Table 2: Presence of informed decision-making documentation: traditional care vs. intervention†
Documented element* Traditional care Recall intervention p
PSA discussion 12.5% 47.8% 0.05
At least one downside 5.0% 43.5% 0.01
Patient preference 20.0% 43.5% 0.09
† Mann Whitney-U test, number of medical providers = 14.
* PSA discussion: Generic reference to or specific details evidencing at least some "discussion." At least one downside: Generic reference to having 
discussed, or specific documentation of, at least one downside of PSA screening. Patient preference: Documentation that the patient does or does 
not wish to proceed with screening.BMC Family Practice 2009, 10:75 http://www.biomedcentral.com/1471-2296/10/75
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sions actually took place and have instead measured only
patient  intentions  to be screened rather than provider
orders for PSA tests. Finally, a recent systematic review
indicates that only a very small number of interventions
to educate and activate patients have been administered
outside of clinical settings [7].
Conclusion
In summary, this patient recall intervention appeared to
activate and enhance opportunities for discussions of
prostate cancer screening among male patients and their
primary care providers, although not as frequently as
desired. As currently configured, we cannot recommend
this recall program for prostate cancer or other controver-
sial screening tests. This type of intervention may be of
greater interest and acceptability to patients if a future ver-
sion promotes screening discussions in the context of a
broader range of health maintenance activities and
includes more detailed, low-literacy information designed
to educate patients in advance of clinic visits.
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